| ONGLYZA™ (saxagliptin) U.S. Label Update Provides Further Evidence Regarding ... - Business Wire (press release) |
|
|
Business Wire (press release) The renal study investigated the safety and efficacy of ONGLYZA in patients with moderate to severe renal impairment or end-stage renal disease (ESRD). The 12-week data showed that ONGLYZA 2.5 mg once daily significantly improved glycoslated hemoglobin |